KLRK1 and neoplasm: The utilization of NKG2D-based CARs for CAR T cell and CAR NK cell design was successfully proven in other studies, and CD3ζ downstream signaling was described to direct anti-tumor activity in macrophages making it suitable for a cross-comparison of CAR T cells, CAR NK cells, and CAR macrophages.21